AlphaCore Capital LLC Grows Stake in Genmab A/S Sponsored ADR $GMAB

AlphaCore Capital LLC increased its position in Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 863.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 20,435 shares of the company’s stock after acquiring an additional 18,313 shares during the period. AlphaCore Capital LLC’s holdings in Genmab A/S were worth $627,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Osaic Holdings Inc. boosted its position in Genmab A/S by 37.8% in the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock worth $33,000 after purchasing an additional 440 shares during the last quarter. CWM LLC lifted its stake in shares of Genmab A/S by 50.5% in the 2nd quarter. CWM LLC now owns 1,797 shares of the company’s stock worth $37,000 after purchasing an additional 603 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in shares of Genmab A/S by 124.9% in the second quarter. EverSource Wealth Advisors LLC now owns 2,114 shares of the company’s stock worth $44,000 after buying an additional 1,174 shares during the last quarter. Cromwell Holdings LLC boosted its holdings in shares of Genmab A/S by 136.3% in the third quarter. Cromwell Holdings LLC now owns 1,531 shares of the company’s stock worth $47,000 after buying an additional 883 shares during the last quarter. Finally, Jones Financial Companies Lllp grew its position in Genmab A/S by 29.1% during the third quarter. Jones Financial Companies Lllp now owns 1,951 shares of the company’s stock valued at $57,000 after buying an additional 440 shares during the period. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Price Performance

NASDAQ:GMAB opened at $29.44 on Friday. The firm has a market capitalization of $18.91 billion, a price-to-earnings ratio of 18.99, a PEG ratio of 1.20 and a beta of 0.90. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.02 and a quick ratio of 2.01. The business has a 50 day simple moving average of $31.91 and a 200-day simple moving average of $30.18. Genmab A/S Sponsored ADR has a 1 year low of $17.24 and a 1 year high of $35.43.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings results on Tuesday, February 17th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.46 by ($0.41). The company had revenue of $1.06 billion for the quarter, compared to analysts’ expectations of $1.06 billion. Genmab A/S had a net margin of 25.89% and a return on equity of 17.35%. Equities analysts forecast that Genmab A/S Sponsored ADR will post 1.45 EPS for the current year.

Analysts Set New Price Targets

Several research firms have weighed in on GMAB. HC Wainwright increased their price target on shares of Genmab A/S from $39.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. Guggenheim reduced their price objective on Genmab A/S from $45.00 to $40.00 and set a “buy” rating for the company in a research note on Monday, February 23rd. Wall Street Zen downgraded Genmab A/S from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Zacks Research lowered Genmab A/S from a “strong-buy” rating to a “hold” rating in a report on Friday, October 31st. Finally, Jefferies Financial Group initiated coverage on Genmab A/S in a research note on Tuesday, February 17th. They issued a “buy” rating and a $41.50 price objective on the stock. Six analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Genmab A/S currently has a consensus rating of “Moderate Buy” and an average price target of $40.70.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.